Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Working Capital Changes: 2013-2024

Historic Other Working Capital Changes for Zevra Therapeutics (ZVRA) over the last 11 years, with Dec 2024 value amounting to $2.2 million.

  • Zevra Therapeutics' Other Working Capital Changes rose 249.60% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 469.72%. This contributed to the annual value of $2.2 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Zevra Therapeutics' Other Working Capital Changes is $2.2 million, which was up 36,281.45% from $6,124 recorded in FY2022.
  • In the past 5 years, Zevra Therapeutics' Other Working Capital Changes registered a high of $2.2 million during FY2024, and its lowest value of -$271,000 during FY2020.
  • For the 2-year period, Zevra Therapeutics' Other Working Capital Changes averaged around $1.1 million, with its median value being $1.1 million (2022).
  • Per our database at Business Quant, Zevra Therapeutics' Other Working Capital Changes slumped by 1,116.35% in 2020 and then surged by 375.10% in 2022.
  • Zevra Therapeutics' Other Working Capital Changes (Yearly) stood at -$271,000 in 2020, then soared by 100.48% to $1,289 in 2021, then spiked by 375.10% to $6,124 in 2022, then reached $2.2 million in 2024.